ANSWER: C

Rationale:

In a patient with type 2 diabetes and albuminuria, an ACEi is the drug of first choice for the second antihypertensive agent. ACEi agents reduce intraglomerular pressure by dilating the efferent arteriole via blockade of angiotensin II (Ang II)-mediated vasoconstriction, independently lowering uACR and slowing CKD progression beyond blood pressure reduction alone. The RENAAL and IDNT trials — though conducted with angiotensin receptor blockers (ARBs) — established the class effect, and MICRO-HOPE confirmed ACEi benefit in diabetic nephropathy. ACEi or ARB therapy is recommended by ACC/AHA and KDIGO guidelines as first-line add-on therapy when uACR exceeds 30 mg/g in diabetic patients. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect — beta-blockers are not first-line add-on agents in diabetic CKD with albuminuria; they may mask hypoglycemia symptoms and have no established antiproteinuric benefit.
• Option B: Option B is incorrect — while thiazide diuretics lower BP effectively in African American patients, they do not provide the specific nephroprotective and antiproteinuric effect of RAAS blockade and are not the preferred add-on in this clinical context.
• Option D: Option D is incorrect — non-dihydropyridine CCBs such as diltiazem have some antiproteinuric properties in vitro but are not guideline-recommended as first-line nephroprotective agents and carry negative chronotropic and dromotropic risks.
• Option E: Option E is incorrect — centrally acting agents such as clonidine are reserved for refractory hypertension and have no nephroprotective indication; they carry significant adverse effect burden including rebound hypertension on discontinuation.

ANSWER: C

Rationale:

An eGFR decline of up to 30% from baseline within the first two to four months of initiating ACEi or ARB therapy is expected, acceptable, and does not warrant discontinuation — it reflects the intended reduction in intraglomerular hypertension and is associated with better long-term renal outcomes. Mr. R.T.'s decline from 62 to 57 mL/min/1.73 m² represents an 8% reduction, well within acceptable limits. His BP remains above target and his potassium at 5.1 mEq/L is mildly elevated but not a contraindication to uptitration. Uptitrating to 20 mg with close follow-up is the appropriate next step. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect — discontinuation based on an 8% eGFR decline would deprive the patient of nephroprotective benefit; discontinuation is considered only if eGFR falls more than 30% or potassium exceeds 5.5 mEq/L.
• Option B: Option B is incorrect — adding spironolactone in a patient with CKD and a potassium of 5.1 mEq/L carries a significant risk of dangerous hyperkalemia and is not appropriate at this stage.
• Option D: Option D is incorrect — ARBs and ACEis produce equivalent eGFR changes through the same efferent arteriolar mechanism; switching class does not mitigate the hemodynamic response.
• Option E: Option E is incorrect — chlorthalidone would lower BP and may slightly reduce potassium, but the priority is optimizing the nephroprotective agent already initiated rather than adding a second drug before the first is at target dose.

ANSWER: C

Rationale:

ACEi-induced cough is a class effect mediated by bradykinin accumulation secondary to inhibition of kininase II, the enzyme responsible for both angiotensin I conversion and bradykinin degradation. It occurs in 10–15% of patients overall and up to 30–40% of East Asian patients. Because the effect is class-wide, switching to a different ACEi (Option E) will not resolve the cough. The appropriate substitution is an ARB such as losartan, which blocks the AT1 receptor downstream without affecting bradykinin metabolism, preserving antiproteinuric and nephroprotective efficacy while eliminating the cough. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect — cough suppression with dextromethorphan does not address the pharmacological cause and is not guideline-recommended management for ACEi cough.
• Option B: Option B is incorrect — ACEi cough is dose-independent in most patients; reducing the dose is unlikely to resolve the symptom and would sacrifice BP and renoprotective effect.
• Option D: Option D is incorrect — substituting a dihydropyridine CCB would abandon RAAS blockade entirely, losing the antiproteinuric and nephroprotective benefit that has produced a meaningful uACR reduction; RAAS blockade must be maintained in this patient.
• Option E: Option E is incorrect — all ACEi agents produce cough through the same bradykinin-dependent mechanism; no ACEi has a demonstrably lower cough incidence in head-to-head trials.

ANSWER: E

Rationale:

Finerenone is a non-steroidal, selective MRA studied in the FIDELIO-DKD and FIGARO-DKD trials, which demonstrated statistically significant reductions in composite cardiorenal endpoints — including sustained eGFR decline, kidney failure, and cardiovascular death — in patients with type 2 diabetes and CKD with albuminuria, on background RAAS blockade. Mr. R.T.'s profile (DM, uACR 75 mg/g, eGFR 55, on ARB) meets the studied population. The primary risk is hyperkalemia, which occurred more frequently in the finerenone arm than placebo; regular potassium monitoring is mandatory. Option A: Option C: Option D: Option B:

• Option A: Option A is incorrect — finerenone's primary evidence base is in diabetic CKD, not HFrEF; steroidal MRAs such as spironolactone and eplerenone carry the HFrEF indication.
• Option C: Option C is incorrect — finerenone is not equivalent to spironolactone for this indication; the FIDELIO/FIGARO trials were conducted specifically with finerenone, and spironolactone lacks equivalent cardiorenal outcome data in diabetic CKD and carries greater risk of gynecomastia and hyperkalemia in CKD patients due to its steroidal structure.
• Option D: Option D is incorrect — finerenone was studied and found beneficial in patients with eGFR as low as 25 mL/min/1.73 m²; eGFR below 60 is not a contraindication, though potassium and eGFR must be checked before initiation.
• Option B: Option B is incorrect — the FIGARO-DKD trial specifically included patients with uACR as low as 30 mg/g, demonstrating benefit across the albuminuria spectrum; there is no threshold of 300 mg/g required for initiation. CASE 2 — Ms. P.W. is a 29-year-old woman with chronic hypertension (BP 148/94 mmHg) on amlodipine 5 mg and lisinopril 10 mg daily who is planning pregnancy within six months. She has no CKD, no diabetes, and no other comorbidities.

ANSWER: C

Rationale:

ACEi and ARB agents are absolutely contraindicated in pregnancy, carrying FDA Pregnancy Category X (formerly) or equivalent teratogenicity warnings. In the second and third trimesters, RAAS blockade causes fetal renal tubular dysplasia, oligohydramnios, skull hypoplasia, limb contractures, and neonatal renal failure — collectively termed ACEi fetopathy. Given that Ms. P.W. is planning pregnancy within six months, starting an ACEi is inappropriate; she should be counseled to use reliable contraception and avoid RAAS blockers until after pregnancy is complete. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect — dihydropyridine CCBs, particularly nifedipine extended-release, are considered acceptable antihypertensive agents in pregnancy with no established teratogenicity; they are commonly used for gestational hypertension and preeclampsia management.
• Option B: Option B is incorrect — labetalol (a combined alpha- and beta-blocker) is one of the most widely used and guideline-endorsed antihypertensives in pregnancy; it is not contraindicated.
• Option D: Option D is incorrect — methyldopa has the longest safety record in pregnancy and remains a first-line option in many international guidelines for hypertension in pregnant patients.
• Option E: Option E is incorrect — while thiazide diuretics are generally avoided in the third trimester due to volume depletion concerns, they are not absolutely contraindicated in women planning pregnancy and carry no established teratogenicity comparable to ACEi agents.

ANSWER: B

Rationale:

The clinical picture — hypertension above 160/110 mmHg after 20 weeks gestation, severe headache, and significant proteinuria — defines preeclampsia with severe features. Acute severe hypertension in pregnancy requires rapid treatment to prevent maternal cerebrovascular and cardiac complications. Guideline-endorsed acute agents include intravenous labetalol, intravenous hydralazine, and oral immediate-release nifedipine. Intravenous labetalol (combined alpha-beta blockade) and hydralazine (direct arteriolar vasodilator) are the most commonly used and best-studied first-line acute agents per ACOG and SMFM guidelines. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect — gestational hypertension is defined by BP elevation without proteinuria after 20 weeks; this patient has both severe-range BP and significant proteinuria, making preeclampsia with severe features the correct diagnosis. Methyldopa is not appropriate for acute severe hypertension management.
• Option C: Option C is incorrect — intravenous nicardipine is sometimes used but is not listed as a primary first-line agent in major North American guidelines for acute severe hypertension in pregnancy; labetalol and hydralazine have superior guideline support.
• Option D: Option D is incorrect — oral dose escalation of a maintenance antihypertensive is not an appropriate response to acute severe hypertension in the inpatient setting; IV agents are required for BP above 160/110 in the acute context.
• Option E: Option E is incorrect — this is clearly preeclampsia with severe features, not a non-pregnancy urgency; clonidine has no established role in acute severe hypertension in pregnancy and carries rebound hypertension risk.

ANSWER: D

Rationale:

Both nifedipine and labetalol transfer into breast milk in low concentrations and are considered compatible with breastfeeding by the American Academy of Pediatrics (AAP) and most lactation guidelines. These are the most widely recommended postpartum antihypertensives for breastfeeding women. Option A: Option B: Option C: Option E:

• Option A: Option A is incorrect — while captopril has low breast milk transfer and some guidelines conditionally permit it, it is not the preferred choice; ACEi agents in general are approached with caution postpartum in breastfeeding because of theoretical neonatal renal effects, and nifedipine or labetalol are preferred first-line options.
• Option B: Option B is incorrect — losartan and other ARBs are not recommended during breastfeeding due to insufficient safety data and the same theoretical neonatal RAAS suppression concerns that contraindicate them in pregnancy; ARBs are generally avoided postpartum in breastfeeding patients.
• Option C: Option C is incorrect — atenolol accumulates in breast milk at concentrations higher than maternal plasma, with documented reports of neonatal bradycardia and hypoglycemia; it is specifically listed as an agent to avoid during breastfeeding, unlike labetalol which does not accumulate to the same degree.
• Option E: Option E is incorrect — spironolactone has limited postpartum antihypertensive evidence and is metabolized to canrenone, which is excreted in breast milk; it is not a recommended agent for postpartum hypertension management in breastfeeding women and lacks guideline endorsement for this indication.

ANSWER: B

Rationale:

Estrogen-containing contraceptives raise blood pressure through stimulation of hepatic angiotensinogen synthesis, increasing substrate availability for the renin-angiotensin-aldosterone system (RAAS) and promoting sodium and water retention. The BP elevation is typically modest (2–4 mmHg systolic) in normotensive women but can be more pronounced in susceptible individuals. Women with a history of hypertension should have BP monitored after initiating COCs; those with uncontrolled hypertension or prior hypertension-related target organ damage are candidates for progestin-only alternatives. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect — COCs do have a clinically meaningful pressor effect mediated through the RAAS and are not categorically safe in all women with hypertension history; they require individualized risk assessment.
• Option C: Option C is incorrect — COCs increase, not decrease, aldosterone-axis activity through angiotensinogen upregulation; they do not lower BP.
• Option D: Option D is incorrect — progestin-only contraceptives do not carry the same hypertensive risk; they lack the estrogen-mediated angiotensinogen stimulus and are preferred alternatives in women for whom estrogen-containing contraceptives are contraindicated.
• Option E: Option E is incorrect — COCs are not absolutely contraindicated in all women who have ever had a BP elevation; women with prior hypertension whose BP is now well-controlled may use COCs with appropriate monitoring, though shared decision-making and individual risk assessment are essential. CASE 3 — Mr. H.K. is a 58-year-old man who suffered an acute anterior STEMI 6 weeks ago, treated with primary PCI. Post-discharge echocardiogram shows LVEF 35% (HFrEF). He is currently on metoprolol succinate 25 mg daily and aspirin. BP at today's follow-up is 152/88 mmHg. He has no CKD and no diabetes.

ANSWER: B

Rationale:

In a patient with recent MI and reduced LVEF (HFrEF, defined as LVEF below 40%), an ACEi is a Class I indication per ACC/AHA guidelines. ACEi therapy post-MI reduces cardiac remodeling, prevents progressive LV dilation, reduces re-infarction risk, and lowers mortality — benefits established in SAVE (captopril), AIRE (ramipril), and TRACE (trandolapril) trials. Lisinopril is appropriate, started at low dose and titrated. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect — while amlodipine is well-tolerated in heart failure (PRAISE-2 established neutral effect), it does not carry the mortality-reducing indication that ACEi therapy provides in post-MI LV dysfunction and is not the priority add-on.
• Option C: Option C is incorrect — non-dihydropyridine CCBs such as diltiazem are contraindicated in HFrEF due to their negative inotropic effect; use in this setting can precipitate acute decompensation.
• Option D: Option D is incorrect — thiazide diuretics lower BP but have no mortality benefit in post-MI LV dysfunction; they are not the priority add-on when ACEi therapy has not yet been initiated.
• Option E: Option E is incorrect — clonidine has no evidence for mortality benefit post-MI, causes significant rebound hypertension on discontinuation, and is not guideline-recommended in this clinical context; it is also poorly tolerated in elderly patients.

ANSWER: D

Rationale:

In HFrEF, beta-blocker therapy should be uptitrated to the maximum tolerated dose based on landmark trial evidence. MERIT-HF used metoprolol succinate at a target of 200 mg daily and demonstrated a 34% reduction in all-cause mortality. Titration from the current 50 mg toward 200 mg, as tolerated by heart rate and BP, is the guideline-recommended approach and confers incremental benefit. Option A: Option C: Option B: Option E:

• Option A: Option A is incorrect — beta-blocker therapy is not discontinued when LVEF recovers; the TRED-HF trial demonstrated that premature discontinuation of guideline-directed medical therapy (GDMT) in recovered HFrEF leads to recurrent LV dysfunction in a substantial proportion of patients.
• Option C: Option C is incorrect — both metoprolol succinate and carvedilol are guideline-endorsed in HFrEF with equivalent evidence; neither is universally superior, and switching without clinical indication is not recommended. Carvedilol is not preferred over metoprolol succinate in all post-MI patients.
• Option B: Option B is incorrect — ivabradine is an adjunct agent for HFrEF with persistent symptoms and heart rate above 70 bpm on maximally tolerated beta-blockade; it does not replace beta-blockers and is not preferred over them.
• Option E: Option E is incorrect — atenolol does not have the mortality data in HFrEF that metoprolol succinate does; MERIT-HF used the succinate (extended-release) formulation specifically, and atenolol is not guideline-endorsed for HFrEF.

ANSWER: C

Rationale:

Dihydropyridine CCB-induced peripheral edema results from preferential arteriolar dilation without equivalent venodilation, increasing transcapillary hydrostatic pressure in the dependent limbs. Importantly, this edema does not reflect fluid overload or worsening heart failure — it is a hemodynamic redistributive phenomenon. ACEi agents, through venodilation mediated by bradykinin and nitric oxide, reduce the transcapillary pressure gradient and can significantly attenuate dihydropyridine-induced peripheral edema. This combination strategy — ACEi plus dihydropyridine CCB — is also the basis of the ACCOMPLISH trial, which demonstrated superior cardiovascular outcomes with amlodipine plus benazepril versus HCTZ plus benazepril. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect — loop diuretics treat volume overload; CCB-induced peripheral edema is not a volume-overload state, and adding furosemide risks intravascular volume depletion without resolving the hemodynamic cause of the edema.
• Option B: Option B is incorrect — amlodipine provides BP control and cardiovascular benefit in this post-MI HFrEF patient; substituting HCTZ forfeits these benefits and does not address the mechanism of the edema.
• Option D: Option D is incorrect — the absence of weight gain and worsening dyspnea with positional edema that worsens by end of day is characteristic of CCB-induced edema, not decompensated heart failure; immediate discontinuation is not warranted.
• Option E: Option E is incorrect — reducing amlodipine dose may partially reduce edema but is not the preferred strategy when the ACEi can address the underlying hemodynamic mechanism while maintaining BP control.

ANSWER: E

Rationale:

In a patient with prior MI and LV dysfunction (now recovered), ACEi and beta-blocker therapy are maintained indefinitely per ACC/AHA guidelines, as the mortality and remodeling prevention benefit is long-term and not predicated on ongoing LV dysfunction. The TRED-HF trial specifically demonstrated that GDMT withdrawal in recovered HFrEF leads to LV dysfunction recurrence in approximately 40% of patients within six months. Amlodipine, as an add-on BP-lowering agent without independent mortality benefit in this context, can be reconsidered if BP is well-controlled on the two-drug backbone. Option A: Option C: Option D: Option B:

• Option A: Option A is incorrect — discontinuing all three agents risks BP elevation, LV dysfunction recurrence, and loss of post-MI mortality benefit; this is not guideline-supported.
• Option C: Option C is incorrect — metoprolol succinate continuation post-MI regardless of LVEF recovery is a Class I recommendation; the beta-blocker benefit is not contingent on ongoing reduced EF.
• Option D: Option D is incorrect — amlodipine discontinuation does not cause rebound coronary vasospasm; this is not a pharmacological property of dihydropyridine CCBs. Rebound phenomena are associated with abrupt discontinuation of beta-blockers and clonidine, not amlodipine.
• Option B: Option B is incorrect — ACEi therapy post-MI should be continued indefinitely in patients with LV dysfunction history, regardless of EF recovery; the SAVE trial demonstrated long-term mortality benefit with captopril continued beyond the period of measurable LV dysfunction. CASE 4 — Mr. G.O. is a 72-year-old man with isolated systolic hypertension (average home BP 168/72 mmHg, pulse pressure 96 mmHg). He has no diabetes, CKD, coronary artery disease, or heart failure, and takes no antihypertensive medications. He is cognitively intact and functionally independent.

ANSWER: E

Rationale:

Isolated systolic hypertension in elderly patients is the most common hypertension phenotype in individuals over 60 and carries significant cardiovascular risk. The pivotal trials are SHEP (Systolic Hypertension in the Elderly Program), which demonstrated a 36% reduction in stroke incidence with low-dose chlorthalidone-based therapy, and Syst-Eur (Systolic Hypertension in Europe), which demonstrated comparable benefit with nitrendipine (a dihydropyridine CCB). These trials form the specific evidence base for ISH treatment and establish both thiazide-type diuretics and dihydropyridine CCBs as first-line agents. Option A: Option B: Option D: Option C:

• Option A: Option A is incorrect — MICRO-HOPE studied ramipril in diabetic patients at high cardiovascular risk; it was not an ISH-specific trial and did not study a predominantly elderly ISH population.
• Option B: Option B is incorrect — the LIFE trial compared losartan to atenolol and demonstrated superiority of losartan in reducing stroke specifically, but LIFE was not an ISH-specific trial and included a broad hypertensive population with LVH; it does not form the primary ISH evidence base.
• Option D: Option D is incorrect — beta-blockers are generally considered less effective than diuretics and CCBs in elderly ISH, and MERIT-HF studied beta-blockade in HFrEF, not ISH; extrapolation is not appropriate.
• Option C: Option C is incorrect — aliskiren (a direct renin inhibitor) failed to demonstrate clinical outcome benefit in high-risk patients in the ALTITUDE trial and is not indicated for first-line hypertension management; it carries risks of hyperkalemia and worsening renal function.

ANSWER: C

Rationale:

Mr. G.O. has an inadequate BP response to chlorthalidone monotherapy, mild hypokalemia (potassium 3.4 mEq/L), and new pre-diabetes (fasting glucose 108 mg/dL, above the 100 mg/dL threshold). Adding a dihydropyridine CCB such as amlodipine is appropriate for additional BP lowering — consistent with ACCOMPLISH trial evidence. Potassium repletion (oral supplementation) addresses the hypokalemia without requiring drug class change. The pre-diabetes finding warrants counseling and monitoring but does not mandate discontinuation of an effective antihypertensive in a high-CV-risk elderly patient. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect — increasing chlorthalidone dose will worsen both hypokalemia and the metabolic glucose effect; dose escalation before adding a second class is not the preferred strategy once metabolic adverse effects are emerging.
• Option B: Option B is incorrect — hydrochlorothiazide has a shorter half-life and somewhat less potent BP-lowering effect than chlorthalidone; it does not have a meaningfully more favorable metabolic profile and would represent a downgrade without clinical benefit.
• Option D: Option D is incorrect — discontinuing an effective antihypertensive with strong ISH trial evidence because of a fasting glucose of 108 mg/dL is disproportionate; pre-diabetes in elderly patients warrants lifestyle counseling and monitoring, not immediate antihypertensive class substitution.
• Option E: Option E is incorrect — amiloride can correct hypokalemia through potassium-sparing diuresis and provides modest additional BP lowering, but adding amlodipine is a more effective next step for BP control; amiloride alone would not adequately address the incomplete BP response.

ANSWER: B

Rationale:

The J-curve hypothesis describes an observed increase in adverse cardiovascular outcomes — particularly coronary events — when diastolic BP is reduced below a threshold value, most consistently below 70 mmHg in patients with established CAD or high coronary risk. The biological rationale is that coronary perfusion occurs predominantly during diastole, and excessive diastolic reduction reduces coronary perfusion pressure, particularly in patients with fixed coronary stenoses. Evidence from the INVEST, HOT, and SPRINT trials suggests a diastolic threshold around 65–70 mmHg below which coronary risk may increase in high-risk populations. At a diastolic of 68 mmHg, Mr. G.O. is approaching this range and warrants monitoring. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect — the J-curve applies primarily to diastolic, not systolic, BP reduction; lowering systolic BP below 140 mmHg is guideline-recommended and reduces stroke risk in elderly ISH patients without evidence of increased systolic J-curve risk at guideline targets.
• Option C: Option C is incorrect — the J-curve has supporting observational data from multiple large trials, though causality interpretation is complex because low diastolic BP may also reflect underlying arterial stiffness or frailty; it is not purely theoretical.
• Option D: Option D is incorrect — the J-curve phenomenon relates specifically to diastolic pressure in coronary-risk patients; it does not apply equally to systolic and diastolic BP and is not the primary reason for modified treatment targets in elderly patients.
• Option E: Option E is incorrect — a diastolic below 80 mmHg alone is not a threshold for discontinuation; the clinical concern arises primarily below 65–70 mmHg, and management involves monitoring and potentially reducing the diuretic dose rather than stopping all therapy.

ANSWER: B

Rationale:

The SPRINT MIND (Memory and cognition IN Decreased hypertension) sub-study of the SPRINT trial demonstrated that intensive systolic BP lowering to below 120 mmHg (versus the standard target of below 140 mmHg) significantly reduced the incidence of new mild cognitive impairment (MCI) by 19% and produced a non-significant trend toward reduced probable dementia. Accumulated epidemiological and interventional data consistently associate midlife hypertension with increased dementia risk, and BP treatment — particularly in the 50s and 60s — is associated with reduced long-term cognitive decline. Mr. G.O.'s antihypertensive therapy is not a likely cause of his cognitive symptoms; untreated or undertreated hypertension poses the greater long-term cognitive risk. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect — antihypertensive therapy at guideline BP targets does not accelerate cognitive decline; the weight of evidence is in the opposite direction.
• Option C: Option C is incorrect — no antihypertensive class has been shown to have uniquely superior neuroprotective properties isolated from BP lowering itself; any agent that effectively lowers BP likely confers similar indirect cognitive benefit.
• Option D: Option D is incorrect — antihypertensive therapy is not discontinued based on age or mild cognitive complaints; stopping therapy in an elderly patient with ISH risks stroke, one of the strongest proximate causes of vascular dementia.
• Option E: Option E is incorrect — multiple large trials, including SPRINT MIND, Syst-Eur, and long-term observational studies, have specifically examined the relationship between antihypertensive treatment and cognition; this is an active and evidenced research area. CASE 5 — Ms. L.V. is a 44-year-old woman with hypertension (BP 158/96 mmHg) and moderate persistent asthma managed with a long-acting beta-2 agonist (salmeterol) and inhaled corticosteroid (fluticasone). She has no CKD, no diabetes, no heart failure, and has not previously been on antihypertensive therapy.

ANSWER: C

Rationale:

Non-selective beta-adrenergic antagonists such as propranolol block both beta-1 (cardiac) and beta-2 (bronchial smooth muscle) receptors. Beta-2 receptor blockade in the airways prevents bronchodilatory tone, increases airway resistance, and can precipitate acute bronchospasm — even at doses used clinically for hypertension. This effect is an FDA-labeled contraindication in patients with reactive airway disease, including asthma. Beta-1 selective agents (metoprolol, atenolol, bisoprolol) have reduced but not eliminated bronchospasm risk and are used with caution in asthma when no alternative exists. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect — ACEi-induced cough is a class effect distinct from bronchoconstriction; while cough can worsen asthma symptoms, ACEi cough does not involve bronchospasm physiology and ACEi agents are not contraindicated in asthma, though the cough overlap may complicate symptom monitoring.
• Option B: Option B is incorrect — thiazide diuretics have no bronchoconstriction mechanism and are not contraindicated in asthma; they are acceptable antihypertensives in this patient.
• Option D: Option D is incorrect — dihydropyridine CCBs have no bronchoconstrictive properties; amlodipine is suitable for use in asthmatic patients and may be a preferred first-line agent in this case.
• Option E: Option E is incorrect — ARBs do not increase leukotriene synthesis and have no established adverse effect on airway inflammation; losartan is not contraindicated in asthma and is an appropriate antihypertensive choice.

ANSWER: B

Rationale:

Thiazide and thiazide-like diuretics cause renal potassium wasting through increased sodium delivery to the cortical collecting duct, stimulating aldosterone-mediated potassium secretion. Beta-2 adrenergic agonists, including LABAs, cause transcellular potassium shift into cells by stimulating Na+/K+-ATPase activity — an effect independent of renal excretion. The combined pharmacological effect of a LABA plus a thiazide diuretic can produce clinically significant hypokalemia, particularly in patients with borderline baseline potassium or high LABA doses. Serum potassium should be checked before and within four to six weeks of initiating chlorthalidone in patients on regular beta-agonist therapy. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect — chlorthalidone has no pharmacological interaction with beta-2 receptor expression or upregulation; this mechanism does not exist.
• Option C: Option C is incorrect — chlorthalidone does not meaningfully affect theophylline clearance; theophylline is primarily metabolized by CYP1A2 and CYP3A4 with clinically relevant interactions from fluoroquinolones and macrolides, not thiazides.
• Option D: Option D is incorrect — chlorthalidone causes volume contraction, not retention; it has no effect on bronchodilatory efficacy of LABA therapy.
• Option E: Option E is incorrect — the opposite is true; both LABAs and thiazides lower serum potassium through different mechanisms, and monitoring is essential after adding either agent to a patient already on the other.

ANSWER: B

Rationale:

ACC/AHA and JNC guidelines consistently recommend dietary sodium restriction as an adjunct to pharmacological therapy across all hypertension phenotypes. Meta-analyses confirm that reducing dietary sodium intake from typical Western levels (approximately 3.5–4 g/day) to below 2.3 g/day reduces systolic BP by 4–6 mmHg in hypertensive patients, with greater effects in salt-sensitive individuals and African American patients. This reduction is clinically meaningful and additive to medication effects. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect — lifestyle modification is recommended as lifelong adjunctive therapy alongside medications; pharmacological BP control does not eliminate the cardiovascular benefit of sodium restriction, weight management, and physical activity.
• Option C: Option C is incorrect — moderate aerobic exercise is not contraindicated in asthmatic patients; exercise-induced bronchoconstriction is managed with pre-exercise short-acting beta-2 agonist (SABA) use if needed, and regular aerobic conditioning actually improves asthma control in many patients.
• Option D: Option D is incorrect — dietary potassium intake is inversely associated with BP through multiple mechanisms including natriuresis and direct vascular effects; the DASH diet, rich in potassium, reduces systolic BP by approximately 8–14 mmHg; potassium-rich diet is recommended in hypertension management.
• Option E: Option E is incorrect — alcohol restriction is an effective lifestyle intervention; reducing intake to below 14 units per week in hypertensive drinkers lowers systolic BP by 3–4 mmHg; this benefit applies in treated as well as untreated hypertensive patients.

ANSWER: C

Rationale:

This presentation is a hypertensive urgency — severely elevated BP without evidence of acute target organ damage (no papilledema, no focal neurological deficits, no change in renal function, no chest pain or ECG changes). Hypertensive urgency does not require immediate parenteral therapy or ICU admission; the goal is gradual BP reduction over 24–48 hours using oral agents. Restarting the patient's own amlodipine with addition of a short-acting oral agent (such as captopril, clonidine, or labetalol) in a monitored outpatient or emergency department observation setting is appropriate. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect — intravenous nitroprusside with a target of 25% reduction in the first hour is the approach for hypertensive emergency (with acute target organ damage); this patient has urgency without emergency features; excessive acute BP reduction risks ischemic complications from impaired autoregulation.
• Option B: Option B is incorrect — oral clonidine loading is sometimes used for urgency but carries significant rebound hypertension risk if doses are missed, is poorly suited for a patient already demonstrating medication non-adherence, and is not the preferred approach for a patient whose primary agent (amlodipine) is simply unavailable.
• Option D: Option D is incorrect — sublingual nifedipine is no longer recommended due to unpredictable and precipitous BP drops causing reflex tachycardia and ischemic events; it is listed explicitly in guidelines as an agent to avoid in hypertensive urgency.
• Option E: Option E is incorrect — discharging without immediate BP reduction and reassessment is inappropriate for a BP of 188/112 mmHg with symptoms; even hypertensive urgency warrants monitored management before discharge. CASE 6 — Mr. D.F. is a 51-year-old man with resistant hypertension (BP 178/106 mmHg) on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily, with confirmed adherence. Potassium is 3.2 mEq/L, creatinine 1.1 mg/dL. Aldosterone-to-renin ratio is markedly elevated at 52 (ng/dL)/(ng/mL/hr), strongly suggesting primary aldosteronism.

ANSWER: B

Rationale:

In a patient with resistant hypertension and a biochemical profile strongly consistent with primary aldosteronism, spironolactone — a competitive MRA — is the most appropriate pharmacological add-on. It directly antagonizes the mineralocorticoid receptor responsible for the sodium retention, hypokalemia, and volume expansion driving BP elevation in PA. The PATHWAY-2 trial confirmed spironolactone as the most effective fourth-line agent in resistant hypertension, producing the greatest additional BP reduction compared to bisoprolol, doxazosin, or placebo. Spironolactone is used while definitive confirmatory testing (saline suppression testing or CT adrenal imaging) proceeds, as it does not preclude diagnosis and provides immediate therapeutic benefit. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect — adding an ARB while the patient is already on a maximally dosed ACEi constitutes dual RAAS blockade, which is not recommended due to increased risk of hyperkalemia and acute kidney injury without additional cardiovascular benefit (ONTARGET trial).
• Option C: Option C is incorrect — adding a beta-blocker to suppress renin would alter the ARR and confound confirmatory diagnostic testing; it is not the appropriate fourth agent in this clinical scenario.
• Option D: Option D is incorrect — hydralazine lowers BP through direct arteriolar vasodilation but does not address the underlying aldosterone-mediated mechanism; it is an older agent with a complex adverse effect profile (reflex tachycardia, lupus-like syndrome) and is not guideline-preferred in resistant hypertension workup.
• Option E: Option E is incorrect — while doxazosin is one of the agents studied in PATHWAY-2, it was found to be less effective than spironolactone as a fourth agent in resistant hypertension; in a patient with evidence of PA, an MRA is specifically indicated and superior.

ANSWER: A

Rationale:

Surgical outcomes in unilateral PA are well-characterized. While hypokalemia resolves in nearly all patients after successful adrenalectomy, BP normalization — defined as achieving BP below 140/90 mmHg off all antihypertensive medications — occurs in only 30–60% of patients in large outcome studies. Factors associated with failure to normalize BP include longer duration of hypertension before diagnosis (which allows development of essential hypertension and nephrosclerosis), older age, male sex, higher preoperative number of antihypertensive agents, and family history of hypertension. Mr. D.F., at 52 with a long hypertension history requiring three agents, has a meaningful probability of requiring ongoing antihypertensive therapy. Option B: Option C: Option D: Option E:

• Option B: Option B is incorrect — surgical cure of PA is defined by normalization of biochemistry (potassium and ARR), not universal BP normalization; many patients require continued medications.
• Option C: Option C is incorrect — adrenalectomy reliably improves both potassium and BP outcomes; the effect on BP is clinically meaningful even in patients who do not achieve normotension off medications, as medication requirements are typically reduced.
• Option D: Option D is incorrect — longer duration of hypertension before diagnosis is associated with worse, not better, BP outcomes after adrenalectomy; earlier diagnosis and treatment preserve the probability of BP normalization.
• Option E: Option E is incorrect — persistent hypertension after successful adrenalectomy does not invalidate the diagnosis; it reflects coexisting essential hypertension, nephrosclerosis from years of aldosterone-driven end-organ damage, or residual adrenal hyperplasia in the contralateral gland.

ANSWER: A

Rationale:

Despite normalization of aldosterone after adrenalectomy, Mr. D.F. now has emerging CKD with albuminuria (uACR 45 mg/g) — likely representing aldosterone-driven nephrosclerosis from years of PA. The PATHWAY-2 evidence base for spironolactone as the most effective fourth-line agent in resistant hypertension remains applicable. Additionally, in patients with CKD and albuminuria, MRA agents provide antiproteinuric benefit through mineralocorticoid receptor blockade in the kidney, independent of aldosterone levels. Restarting spironolactone at low dose with potassium monitoring is appropriate. Option B: Option C: Option D: Option E:

• Option B: Option B is incorrect — a beta-blocker is a reasonable consideration in some resistant hypertension patients but is not the most appropriate next step here given the CKD with albuminuria, where an MRA addresses both BP and renal protection simultaneously.
• Option C: Option C is incorrect — adding chlorthalidone in a patient with eGFR 58 mL/min/1.73 m² and existing CKD may worsen renal function with volume contraction and does not address the emerging albuminuria; it is not the preferred add-on in this clinical profile.
• Option D: Option D is incorrect — hydralazine is not guideline-recommended as an add-on agent in CKD-associated resistant hypertension; it provides vasodilation without renal or BP target-organ benefit and carries a risk of lupus-like syndrome with prolonged use.
• Option E: Option E is incorrect — while eplerenone has less anti-androgenic effect than spironolactone and produces less gynecomastia, it has weaker mineralocorticoid receptor binding affinity and requires twice-daily dosing; in the absence of current gynecomastia with prior spironolactone use, restarting spironolactone is the more evidence-supported choice.

ANSWER: C

Rationale:

Renal denervation — catheter-based ablation of the renal sympathetic nerves — has been studied in large sham-controlled trials including SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED, both of which demonstrated statistically significant reductions in 24-hour ambulatory BP compared to sham procedure at six months. RADIANCE-HTN SOLO and TRIO similarly showed significant BP reductions with ultrasound-based denervation. These results contrast with the earlier SYMPLICITY HTN-3 trial (which was negative), and the discrepancy is attributed to improved catheter systems and patient selection. The current evidence supports renal denervation as an adjunctive treatment for patients with resistant or uncontrolled hypertension inadequately controlled on optimized pharmacotherapy. It does not replace medications and is not first-line therapy. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect — renal denervation is not first-line therapy for all hypertensive patients; it is reserved for resistant or pharmacologically uncontrolled hypertension in carefully selected patients and requires continued pharmacological therapy.
• Option B: Option B is incorrect — denervation produces BP reductions but does not eliminate the need for antihypertensive medications; it is an adjunct.
• Option D: Option D is incorrect — this overstates the negative data; while SYMPLICITY HTN-3 was negative, subsequent sham-controlled trials with improved methodology demonstrated significant BP reductions.
• Option E: Option E is incorrect — renal denervation is not limited to post-adrenalectomy PA patients; it is a general resistant hypertension intervention applicable across etiologies in appropriate candidates.